Home > Oncology > ASCO GU 2022 > Renal Cell Carcinoma > Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By
Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2, TITAN-RCC
Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related parameters that were associated with efficacy of nivolumab (± ipilimumab) in the treatment of patients with advanced or metastatic clear-cell renal cell carcinoma (RCC). Despite the promising therapeutic efficacy of immune checkpoint inhibitors in RCC, response varies significantly between individual patients. Therefore, predictors of response are urgently needed. The open-label, phase 2 TITAN-RCC trial (NCT02917772) investigates nivolumab monotherapy with additional nivolumab/ipilimumab boost cycles in previously untreated and pre-treated patients with advanced or metastatic RCC with intermediate- and high-risk disease. Participants received nivolumab induction until week 16 and continued with nivolumab maintenance upon remission. Participants who had ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on